Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diarrhea-Pipeline Review, H1 2015

Diarrhea-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diarrhea-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diarrhea-Pipeline Review, H1 2015', provides an overview of the Diarrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diarrhea

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diarrhea

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diarrhea Overview 8

Therapeutics Development 9

Pipeline Products for Diarrhea-Overview 9

Pipeline Products for Diarrhea-Comparative Analysis 10

Diarrhea-Therapeutics under Development by Companies 11

Diarrhea-Therapeutics under Investigation by Universities/Institutes 15

Diarrhea-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Diarrhea-Products under Development by Companies 19

Diarrhea-Products under Investigation by Universities/Institutes 22

Diarrhea-Companies Involved in Therapeutics Development 23

A. Menarini Industrie Farmaceutiche Riunite Srl 23

Ache Laboratorios Farmaceuticos S/A 24

Actelion Ltd 25

Aegis Therapeutics, LLC 26

Assembly Biosciences, Inc. 27

Chiesi Farmaceutici SpA 28

Chongqing Zhifei Biological Products Co., Ltd. 29

Cosmo Pharmaceuticals S.p.A 30

Cubist Pharmaceuticals, Inc. 31

DesignMedix, Inc. 32

DiscoveryBiomed, Inc. 33

Furiex Pharmaceuticals, Inc. 34

GlycoVaxyn AG 35

GP Pharm, S.A. 36

Helsinn Healthcare S.A. 37

Intercept Pharmaceuticals, Inc. 38

Ipsen S.A. 39

Mucosis B.V. 40

Napo Pharmaceuticals, Inc. 41

Nippon Shinyaku Co., Ltd. 42

Novartis AG 43

Paratek Pharmaceuticals, Inc. 44

Pfizer Inc. 45

Prokarium Ltd. 46

Sanofi Pasteur SA 47

Scandinavian Biopharma Holding AB 48

Shire Plc 49

Sigmoid Pharma Limited 50

Summit Corporation plc 51

Syntiron LLC 52

Ventria Bioscience 53

Diarrhea-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Target 55

Assessment by Mechanism of Action 58

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

ACE-527-Drug Profile 64

ACE-920-Drug Profile 66

ACH-04-Drug Profile 67

AKT-10081-Drug Profile 68

ASP-7147-Drug Profile 69

cadazolid-Drug Profile 70

clostridium difficile vaccine-Drug Profile 71

crofelemer DR-Drug Profile 72

Diarrhea Vaccine-Drug Profile 74

diarrhea vaccine-Drug Profile 75

Drugs for CDAD-Drug Profile 76

elsiglutide-Drug Profile 77

eluxadoline-Drug Profile 78

Escherichia coli vaccine-Drug Profile 80

ETEC Adhesin-Based Vaccine-Drug Profile 81

Etvax-Drug Profile 82

fidaxomicin-Drug Profile 84

GVXNSD-133-Drug Profile 87

helicobacter pylori vaccine [Hel-305] (multivalent)-Drug Profile 88

ibodutant-Drug Profile 89

infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine-Drug Profile 90

INX-201-Drug Profile 91

iOWH0-32-Drug Profile 92

lanreotide acetate-Drug Profile 94

obeticholic acid-Drug Profile 96

octreotide-Drug Profile 99

octreotide acetate MAR-Drug Profile 100

Peptide for Enterocolitis and Infectious Diarrhea-Drug Profile 101

PF-06425090-Drug Profile 102

prulifloxacin-Drug Profile 103

PZ-7475-Drug Profile 105

RBX-2660-Drug Profile 106

Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea-Drug Profile 107

Recombinant Proteins for Infectious Diarrhea-Drug Profile 109

rifamycin-Drug Profile 110

Small Molecule to Inhibit EnaC and Activate CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease-Drug Profile 112

Small Molecules for Bacterial Infections-Drug Profile 113

Small Molecules for Diarrhea-Drug Profile 114

Small Molecules for Diarrhea-Drug Profile 115

Small Molecules to Inhibit CFTR for Secretory Diarrhea-Drug Profile 116

SMT-19969-Drug Profile 117

surotomycin-Drug Profile 118

Tetracycline Derivatives for CDAD-Drug Profile 119

Typhetec-Drug Profile 120

Vaccine for Campylobacter Caused Diarrhea-Drug Profile 121

Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea-Drug Profile 123

VEN-100-Drug Profile 124

VP-20621-Drug Profile 126

Yersinia pestis vaccine-Drug Profile 127

Diarrhea-Recent Pipeline Updates 128

Diarrhea-Dormant Projects 155

Diarrhea-Discontinued Products 157

Diarrhea-Product Development Milestones 158

Featured News & Press Releases 158

Appendix 166

Methodology 166

Coverage 166

Secondary Research 166

Primary Research 166

Expert Panel Validation 166

Contact Us 167

Disclaimer 167

List of Tables

Number of Products under Development for Diarrhea, H1 2015 13

Number of Products under Development for Diarrhea-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Diarrhea-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 27

Diarrhea-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 28

Diarrhea-Pipeline by Actelion Ltd, H1 2015 29

Diarrhea-Pipeline by Aegis Therapeutics, LLC, H1 2015 30

Diarrhea-Pipeline by Assembly Biosciences, Inc., H1 2015 31

Diarrhea-Pipeline by Chiesi Farmaceutici SpA, H1 2015 32

Diarrhea-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 33

Diarrhea-Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 34

Diarrhea-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 35

Diarrhea-Pipeline by DesignMedix, Inc., H1 2015 36

Diarrhea-Pipeline by DiscoveryBiomed, Inc., H1 2015 37

Diarrhea-Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 38

Diarrhea-Pipeline by GlycoVaxyn AG, H1 2015 39

Diarrhea-Pipeline by GP Pharm, S.A., H1 2015 40

Diarrhea-Pipeline by Helsinn Healthcare S.A., H1 2015 41

Diarrhea-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 42

Diarrhea-Pipeline by Ipsen S.A., H1 2015 43

Diarrhea-Pipeline by Mucosis B.V., H1 2015 44

Diarrhea-Pipeline by Napo Pharmaceuticals, Inc., H1 2015 45

Diarrhea-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 46

Diarrhea-Pipeline by Novartis AG, H1 2015 47

Diarrhea-Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 48

Diarrhea-Pipeline by Pfizer Inc., H1 2015 49

Diarrhea-Pipeline by Prokarium Ltd., H1 2015 50

Diarrhea-Pipeline by Sanofi Pasteur SA, H1 2015 51

Diarrhea-Pipeline by Scandinavian Biopharma Holding AB, H1 2015 52

Diarrhea-Pipeline by Shire Plc, H1 2015 53

Diarrhea-Pipeline by Sigmoid Pharma Limited, H1 2015 54

Diarrhea-Pipeline by Summit Corporation plc, H1 2015 55

Diarrhea-Pipeline by Syntiron LLC, H1 2015 56

Diarrhea-Pipeline by Ventria Bioscience, H1 2015 57

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Stage and Target, H1 2015 61

Number of Products by Stage and Mechanism of Action, H1 2015 63

Number of Products by Stage and Route of Administration, H1 2015 65

Number of Products by Stage and Molecule Type, H1 2015 67

Diarrhea Therapeutics-Recent Pipeline Updates, H1 2015 132

Diarrhea-Dormant Projects, H1 2015 159

Diarrhea-Dormant Projects (Contd..1), H1 2015 160

Diarrhea-Discontinued Products, H1 2015 161

List of Figures

Number of Products under Development for Diarrhea, H1 2015 13

Number of Products under Development for Diarrhea-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 58

Number of Products by Top 10 Targets, H1 2015 59

Number of Products by Stage and Top 10 Targets, H1 2015 60

Number of Products by Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Top 10 Routes of Administration, H1 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 64

Number of Products by Top 10 Molecule Types, H1 2015 66

Number of Products by Stage and Top 10 Molecule Types, H1 2015 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

Ache Laboratorios Farmaceuticos S/A

Actelion Ltd

Aegis Therapeutics, LLC

Assembly Biosciences, Inc.

Chiesi Farmaceutici SpA

Chongqing Zhifei Biological Products Co., Ltd.

Cosmo Pharmaceuticals S.p.A

Cubist Pharmaceuticals, Inc.

DesignMedix, Inc.

DiscoveryBiomed, Inc.

Furiex Pharmaceuticals, Inc.

GlycoVaxyn AG

GP Pharm, S.A.

Helsinn Healthcare S.A.

Intercept Pharmaceuticals, Inc.

Ipsen S.A.

Mucosis B.V.

Napo Pharmaceuticals, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Paratek Pharmaceuticals, Inc.

Pfizer Inc.

Prokarium Ltd.

Sanofi Pasteur SA

Scandinavian Biopharma Holding AB

Shire Plc

Sigmoid Pharma Limited

Summit Corporation plc

Syntiron LLC

Ventria Bioscience

Diarrhea Therapeutic Products under Development, Key Players in Diarrhea Therapeutics, Diarrhea Pipeline Overview, Diarrhea Pipeline, Diarrhea Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com